http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002511868-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 1998-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2002511868-A |
| titleOfInvention | Calcium blockers for treating proliferative vitreoretinopathy |
| abstract | (57) [Summary]nGlutamate causes migration and proliferation of retinal pigment epithelial cells and / or glial cells, and antagonists of glutamate prevent, treat or reduce migration of retinal pigment epithelium and / or glia and subsequent appearance of proliferative vitreoretinopathy. can do. By administering to a patient a compound capable of reducing glutamate-induced retinal cell migration at a concentration effective to reduce such migration, proliferative vitreoretinopathy can be avoided or managed. |
| priorityDate | 1997-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.